June 11, 2021 Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 7, 2021 Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
May 18, 2021 Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
May 14, 2021 Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 12, 2021 Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
May 10, 2021 Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
April 21, 2021 Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
February 26, 2021 Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®